Introduction to Real World Overall

Real-world overall survival (rwOS) was defined as time from diagnosis to death (censored at last EHR activity).

Real-world overall survival (rwOS) was estimated using the Kaplan-Meier method.

Real-world overall survival (rwOS) was defined as time from 2L initiation to death (censored at last EHR activity).

Real-world overall response rate (rwORR) was calculated as the proportion of patients achieving complete response (CR) or partial response (PR).

4) months, the median real-world overall survival was 24.

G12C [G12C] and KRAS/EGFR/ALK wild type [Triple WT]) diagnosed January 2011 to March 2019 were selected from a US clinico-genomic database; treatment-related characteristics, molecular profiles, real-world overall (rwOS) and progression-free survival (rwPFS) were analyzed.

Median real-world overall survival was 16.

Preliminary outcome analysis showed no difference in real-world overall survival in those with a canonical ESR1 mutation with or without an additional co-occurring subclonal ESR1 mutation.

This study compares the real-world overall survival (OS) of NSCLC patients by smoking history and mutation status.

This study aimed to examine whether the real-world overall survival (OS) has improved in patients with human epidermal growth factor receptor 2-positive (HER2 +) advanced breast cancer (ABC) since the market release of pertuzumab and T-DM1.

While the real-world overall survival in Japanese patients with mRCC in the targeted therapy era improved compared to that previously reported in the cytokine era, there was no clear difference in the survival of poor risk patients between these eras.

Real-world overall survival (OS) information was obtained from insurance claims data and Kaplan-Meier estimates were calculated for molecularly defined patient cohorts.

Aim: To investigate real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) in locally advanced/metastatic urothelial carcinoma postplatinum and postprogrammed death receptor-1/death ligand 1 inhibitors.

In part 1, we quantified the feasibility and reliability of data capture, and estimated the association between rwR status and real-world progression-free survival (rwPFS) and real-world overall survival (rwOS).

Real-world overall survival (OS) was obtained from payor claims data and Kaplan-Meier estimates were calculated.

This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically malignancies.

In cancer trials, two real-world endpoints are particularly of interest: real-world overall survival (rwOS) and real-world time to next treatment (rwTTNT).

Using best tumor response assessments, real-world overall response rates (rwORR) and disease control rates (rwDCR) were described and analyzed using logistic regression.

Time to next treatment (TTNT), time to discontinuation (TTD), real-world overall survival (rwOS) were compared with vs.

We identified iMCD patients in an electronic health record (EHR)-derived dataset and described their clinical characteristics, treatment patterns, and real-world overall survival (rwOS).

Here, we assessed the performance of real-world overall survival (rwOS) from datasets sourced from EHRs by evaluating the ability of the endpoint to reflect expected differences from a previous randomized controlled trial across 5 data sources, after applying inclusion/exclusion criteria.